Blättern Human- und Zahnmedizin nach "Trendelenburg, George Prof. Dr." Betreuer
Anzeige 1-6 von 6
-
Evaluation des therapeutischen Potentials von intravenös appliziertem Metallothionein-II im Schlaganfall Modell der Maus unter Thrombolyse
(2024-03-27)Stroke is the second leading cause of death worldwide. The only available drug therapy is thrombolysis using recombinant tissue-specific plasminogen activator (rtPA), which can only be used to a limited extent due to the ... -
Studie zur Untersuchung des Antibiotika-Einflusses auf Mikrobiom-assoziierte Schlaganfallfolgen im Mausmodell
(2021-07-27)Stroke is the third leading cause of death in Germany and the most common cause of acquired disability. Primary treatment options are limited by a time window and interventions in ischaemic stroke are limited to lysis ... -
Auswirkung der TLR4-Inhibition bei verschiedenen Applikationswegen im Modell des ischämischen Schlaganfalls
(2020-11-10)Stroke is one of the most common diseases today and one of the leading causes for physical and psychological disability. Except of the recanalisation therapies that have been established there are no other therapeutical ... -
Untersuchungen zur Rolle des Silent information regulator 2 (Sirt2) im experimentellen Schlaganfall in Mäusen
(2019-07-22)Sirtuin-2 (Sirt2) is a member of the NAD+-dependent protein deacetylase family. Various members of the sirtuin class have been found to be involved in processes related to longevity, regulation of inflammation, and ... -
Beurteilung des therapeutischen Potenzials von intraperitoneal injiziertem Metallothionein-II im ischämischen Schlaganfallmodell an der Maus
(2019-02-25)All across the globe ischemic strokes are one of the prime contributors to death as well as physical and psychological disability. Even though prospects for therapeutic treatment during the acute phase have experienced ... -
Therapeutisches Potenzial und Langzeiteffekt der TLR4-Inhibition bei der fokalen zerebralen Ischämie
(2016-04-11)Ischemic stroke is known to be one of the leading causes of death worldwide. As therapeutic options especially for treatment beyond 4,5 to 6 hours after the beginning of symptoms are limited, recent studies have focussed ...